IDEAYA Biosciences, Inc. IDYA IDE161 — External Clinical Development Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s ide161 — external clinical development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s IDE161 — external clinical development expenses?
- IDEAYA Biosciences, Inc. (IDYA) reported IDE161 — external clinical development expenses of $1.61M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s IDE161 — external clinical development expenses changed year-over-year?
- IDEAYA Biosciences, Inc.'s IDE161 — external clinical development expenses decreased by 34.4% year-over-year, from $2.45M to $1.61M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s IDE161 — external clinical development expenses?
- Over 3 years (2022 to 2025), IDEAYA Biosciences, Inc.'s IDE161 — external clinical development expenses has grown at a 40.3% compound annual growth rate (CAGR), from $2.75M to $7.6M.
- What does IDE161 — external clinical development expenses mean?
- This metric represents the direct costs incurred by the company for third-party clinical research organizations, laboratory services, and trial site operations specifically associated with the development of the IDE161 therapeutic candidate. It captures the external capital intensity required to advance this specific oncology asset through clinical validation stages. Monitoring these expenses provides insight into the company's investment pace and the progress of its precision medicine pipeline.